Gemeinsame Stellungnahme der DGHO und DGVS zur Nutzenbewertung von Pembrolizumab in Kombination mit Chemotherapie (Ösophaguskarzinom)

• Literatur

• 1 Gesellschaft der epidemiologischen Krebsregister in Deutschland/Robert – Koch Institut. Krebs in Deutschland 2015–2016, Häufigkeiten und Trends. Ösophagus 2020; 12: 28-30
• 2 S3-Leitlinie Diagnostik und Therapie der Plattenepithelkarzinome und Adenokarzinome des Ösophagus, Dezember 2018. https://www.awmf.org/leitlinien/detail/ll/021-023OL.html
• 3 Stahl M. et al. Ösophaguskarzinom, Onkopedia, Dezember 2018. https://www.onkopedia.com/de/onkopedia/guidelines/oesophaguskarzinom/@@guideline/html/index.html
• 4 Sun JM, Shen L, Shah MA. et al. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. Lancet 2021; 398: 759-771
• 5 Möhler M, Maderer A, Thuss-Patience PC. et al. Cisplatin and 5-fluorouracil with or without epidermal growth factor receptor inhibition panitumumab for patients with non-resectable, advanced or metastatic oesophageal squamous cell cancer: a prospective, open-label, randomised phase III AIO/EORTC trial (POWER). Ann Oncol 2020; 31: 228-235
• 6 Metges JP, Kato K, Sun JM. et al First-line pembrolizumab plus chemotherapy versus chemotherapy in advanced esophageal cancer: Longer-term efficacy, safety, and quality-of-life results from the phase 3 KEYNOTE-590 study. 2022 ASCO Gastrointestinal Cancers Symposium
• 7 Cherny NI, Sullivan R, Dafni U. et al. A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). Ann Oncol 2015; 26: 1547-1573
• 8 Cherny NI, Dafni U, Bogaerts J. et al. ESMO-Magnitude of Clinical Benefit Scale version1.1. Ann Oncol 2017; 28: 2340-2366
• 9 Kato K, Cho B, Takahashi M. et al. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase III trial. Lancet Oncol 2019; 20: 1506-1517
• 10 Kojima T, Shah MA, Muro K. et al. KEYNOTE-181 Investigators. Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer. J Clin Oncol 2020; 38 (35) 4138-4148
• 11 Janjigian YY, Shitara K, Möhler M. et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet 2021; 398: 27-40